StocksFundsScreenerSectorsWatchlists
SNDX

SNDX - Syndax Pharmaceuticals Inc Stock Price, Fair Value and News

23.44USD+0.37 (+1.60%)Delayed as of 28 Mar 2024, 11:04 am ET

Market Summary

SNDX
USD23.44+0.37
Delayedas of 28 Mar 2024, 11:04 am
1.60%

SNDX Alerts

  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

SNDX Stock Price

View Fullscreen

SNDX RSI Chart

SNDX Valuation

Market Cap

2.0B

Price/Earnings (Trailing)

-9.36

Price/Sales (Trailing)

14.82

Price/Free Cashflow

-12.21

SNDX Price/Sales (Trailing)

SNDX Profitability

Return on Equity

-37.78%

Return on Assets

-34.16%

Free Cashflow Yield

-8.19%

SNDX Fundamentals

SNDX Revenue

SNDX Earnings

Earnings (TTM)

-209.4M

Earnings Growth (Yr)

-84.91%

Earnings Growth (Qtr)

-41.7%

Breaking Down SNDX Revenue

52 Week Range

12.1423.55
(Low)(High)

Last 7 days

-4%

Last 30 days

0.5%

Last 90 days

7.8%

Trailing 12 Months

5.8%

How does SNDX drawdown profile look like?

SNDX Financial Health

Current Ratio

10

SNDX Investor Care

Shares Dilution (1Y)

24.52%

Diluted EPS (TTM)

-2.98

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
20220000
20211.5M1.5M13.5M139.7M
20201.5M1.5M1.5M1.5M
20191.5M1.5M1.5M1.5M
20182.2M2.3M2.3M1.5M
20171.2M1.2M1.2M2.1M
2016775.3K923.5K1.1M1.2M
2015000627.0K

Tracking the Latest Insider Buys and Sells of Syndax Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 07, 2024
meury william
acquired
-
-
17,000
-
Feb 07, 2024
goldan keith a.
acquired
-
-
46,700
chief financial officer
Feb 07, 2024
morrison briggs
acquired
-
-
17,000
-
Feb 07, 2024
huber martin h. jr.
acquired
-
-
17,000
-
Feb 07, 2024
jarrett jennifer
acquired
-
-
17,000
-
Feb 07, 2024
podlesak dennis
acquired
-
-
34,000
-
Feb 07, 2024
metzger michael a
acquired
-
-
146,250
chief executive officer
Feb 07, 2024
legault pierre
acquired
-
-
17,000
-
Feb 07, 2024
katkin keith
acquired
-
-
17,000
-
Feb 07, 2024
gallagher neil
acquired
-
-
47,813
president, head of r&d

1–10 of 50

Which funds bought or sold SNDX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
added
511
18,811
21,135
-%
Mar 21, 2024
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
new
-
16,855,800
16,855,800
0.06%
Mar 18, 2024
KINGDON CAPITAL MANAGEMENT, L.L.C.
new
-
32,254,800
32,254,800
2.02%
Mar 11, 2024
VANGUARD GROUP INC
added
19.85
41,163,800
93,687,000
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
97.35
35,658,300
54,066,000
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
added
1.03
240,474
717,906
-%
Feb 26, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
sold off
-100
-544,000
-
-%
Feb 26, 2024
Virtu Financial LLC
new
-
258,000
258,000
0.02%
Feb 20, 2024
Quarry LP
new
-
16,208
16,208
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
new
-
533,000
533,000
0.04%

1–10 of 43

Are Funds Buying or Selling SNDX?

Are funds buying SNDX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SNDX
No. of Funds

Unveiling Syndax Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
kynam capital management, lp
6.67%
5,660,000
SC 13G
Feb 14, 2024
point72 asset management, l.p.
3.3%
2,834,499
SC 13G/A
Feb 13, 2024
avidity partners management lp
4.7%
3,950,000
SC 13G/A
Feb 13, 2024
vanguard group inc
5.11%
4,335,353
SC 13G
Feb 08, 2024
wellington management group llp
8.94%
7,585,221
SC 13G/A
Jan 25, 2024
state street corp
5.91%
5,016,224
SC 13G/A
Jan 25, 2024
blackrock inc.
8.3%
7,015,548
SC 13G/A
Oct 31, 2023
point72 asset management, l.p.
4.5%
3,156,982
SC 13G
Oct 05, 2023
frazier life sciences public fund, l.p.
0.0%
0
SC 13G/A
Feb 14, 2023
nantahala capital management, llc
1.4%
975,705
SC 13G/A

Recent SEC filings of Syndax Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Mar 18, 2024
8-K
Current Report
Feb 27, 2024
10-K
Annual Report
Feb 27, 2024
8-K
Current Report
Feb 27, 2024
S-3ASR
S-3ASR
Feb 27, 2024
S-8
Employee Benefits Plan
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
4
Insider Trading

Peers (Alternatives to Syndax Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

Syndax Pharmaceuticals Inc News

Latest updates
Zacks Investment Research2 hours ago

Syndax Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q1
Revenue------126,57612,375379379380379379379380379379379380379379379
Operating Expenses38.2%77,90656,35549,67846,01542,03430,82732,40722,71327,54220,24020,23216,98915,47914,58513,52815,75315,19019,71318,22019,33020,130
  S&GA Expenses31.9%22,77917,26814,91411,96110,1926,9276,8015,8425,6724,7185,8246,0465,9175,0833,6053,4633,9113,8924,1254,4794,791
  R&D Expenses41.0%55,12739,08734,76434,05431,84223,90125,60616,87121,87015,52214,40810,9439,5629,5029,92312,29011,27915,82114,09514,85115,339
Interest Expenses-10.0%63.0070.0035.0040.0043.00-7.00649634623635635638449--------
Net Income-41.7%-72,473-51,146-44,615-41,126-39,19496,198-20,639-22,910-27,723-20,423-20,437-17,062-15,236-14,000-12,829-14,916-14,302-18,837-17,338-18,388-19,398
Net Income Margin0%-1.26*-1.26*-1.15*-1.10*-1.07*0.18*-6.79*-60.31*-56.46*-48.23*-----------
Free Cashflow0%-44,667-44,667-35,385-39,242-22,908100,695-24,958-24,059-22,603-15,645-----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets53.5%61339943146049736040642245024026328030117919310564.0076.0087.0099.0084.00
  Current Assets52.5%58138140944249035839242044823826327929917719210462.0075.0086.0098.0083.00
    Cash Equivalents212.4%29595.0097.0058.0074.0071.0012018922271.0068.0064.0011556.0054.0045.0025.0031.0027.0058.0034.00
  Net PPE-20.0%0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
Liabilities46.6%59.0040.0031.0024.0030.0022.0044.0048.0041.0040.0048.0051.0048.0047.0045.0052.0032.0032.0032.0031.0031.00
  Current Liabilities48.3%58.0039.0030.0024.0029.0021.0031.0031.0021.0029.0024.0025.0019.0015.0012.0019.0018.0018.0017.0016.0016.00
Shareholder's Equity54.3%55435940043646733836237540819921522825213214854.0032.0044.0055.0069.0053.00
  Retained Earnings-8.7%-902-829-778-734-693-653-618-580-543-639-619-596-568-548-527-510-495-481-468-453-439
  Additional Paid-In Capital22.4%1,4561,1901,1791,1701,161994982956952839834825821680675564527525524522492
Shares Outstanding21.8%85.0070.0069.0068.0068.0060.0060.0059.0052.0052.0052.0051.00---------
Float---1,452,442---1,084---833---500---208--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations7.4%-41,349-44,653-35,371-39,228-22,894-28,544-40,306-41,931100,709-24,944-24,045-22,589-15,631-18,297-21,407-15,925-12,727-8,529-12,525-16,831-15,043
  Share Based Compensation0.1%8,3278,3218,0656,2384,2414,3623,9383,4783,9293,3813,2402,7672,0353,0632,1301,8291,5251,5501,3381,5921,472
Cashflow From Investing-140.6%-16,29040,07773,90719,915-137,629-6,793-49,9488,182-59,95626,63121,680-29,228-64,14019,275-78,612-19,0536,59612,364-18,93112,75215,962
Cashflow From Financing13864.5%258,4831,8511,3242,474163,502-13,52521,720557109,7791,7056,020960138,6581,767109,00154,99858.0080.006.0028,4266,145

SNDX Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues:   
License fees$ 0$ 0$ 139,709
Total revenues$ 0$ 0$ 139,709
Type of revenue [extensible list]us-gaap:LicenseMemberus-gaap:LicenseMemberus-gaap:LicenseMember
Operating expenses:   
Research and development$ 163,032$ 118,499$ 88,248
Selling, general and administrative66,92233,25825,241
Total operating expenses229,954151,757113,489
(Loss) income from operations(229,954)(151,757)26,220
Other income (expense):   
Interest expense(208)(3,137)(1,899)
Interest income21,1635,872403
Other (expense) income, net(361)(316)202
Total other income (expense)20,5942,419(1,294)
Net (loss) income(209,360)(149,338)24,926
Net (loss) income attributable to common stockholders$ (209,360)$ (149,338)$ 24,926
Net (loss) income Per Share:   
Basic (loss) earnings per share attributable to common stockholders$ (2.98)$ (2.46)$ 0.48
Diluted (loss) earnings per share attributable to common stockholders$ (2.98)$ (2.46)$ 0.46
Weighted-average common shares used in calculating:   
Basic (loss) earnings per share attributable to common stockholders70,370,51960,760,90652,064,809
Diluted (loss) earnings per share attributable to common stockholders70,370,51960,760,90653,622,904

SNDX Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 295,394$ 74,356
Short-term investments275,304401,446
Short-term deposits6,8858,595
Collaboration receivable, net03,474
Prepaid expenses and other current assets3,2931,915
Total current assets580,876489,786
Long-Term Investments29,8295,469
Property and equipment, net820
Right-of-use asset1,4871,039
Restricted cash217115
Other assets463807
Total assets612,880497,236
Current liabilities:  
Accounts payable9,9614,350
Collaboration payable, net7,2320
Accrued expenses and other current liabilities39,85624,276
Current portion of right-of-use liability1,035434
Current Portion Of Capital Lease125
Total current liabilities58,09629,065
Long-term liabilities:  
Right-of-use liability, less current portion578709
Capital Lease Less Current Portion1013
Total long-term liabilities588722
Total liabilities58,68429,787
Commitments and contingencies (Note 16)
Stockholders' equity:  
Preferred stock, $0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at December 31, 2023 and December 31, 202200
Common stock, $0.0001 par value, 200,000,000 and 100,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; 84,826,632 and 68,111,385 shares outstanding at December 31, 2023 and December 31, 2022, respectively87
Additional paid-in capital1,456,3701,161,288
Accumulated other comprehensive income (loss)218(806)
Accumulated deficit(902,400)(693,040)
Total stockholders' equity554,196467,449
Total liabilities and stockholders' equity$ 612,880$ 497,236
SNDX
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 for the treatment of KMT2A rearranged (KMT2Ar) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
 CEO
 WEBSITEwww.syndax.com
 EMPLOYEES107

Syndax Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Syndax Pharmaceuticals Inc? What does SNDX stand for in stocks?

SNDX is the stock ticker symbol of Syndax Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Syndax Pharmaceuticals Inc (SNDX)?

As of Wed Mar 27 2024, market cap of Syndax Pharmaceuticals Inc is 1.96 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SNDX stock?

You can check SNDX's fair value in chart for subscribers.

What is the fair value of SNDX stock?

You can check SNDX's fair value in chart for subscribers. The fair value of Syndax Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Syndax Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SNDX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Syndax Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether SNDX is over valued or under valued. Whether Syndax Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Syndax Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SNDX.

What is Syndax Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, SNDX's PE ratio (Price to Earnings) is -9.36 and Price to Sales (PS) ratio is 14.82. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SNDX PE ratio will change depending on the future growth rate expectations of investors.